Illumina, Inc. - Common Stock (ILMN)

BBH offers lower costs and concentrated large-cap exposure, while PBE delivers higher dividend income and slightly better five-year returns through a multifactor strategy.

FBT has outperformed RSPH by a wide margin recently. The question is whether you want to own the fund that won last year or the one built to hold up over many years.

RSPH offers broader healthcare exposure with lower volatility and higher dividend yield, while IBB provides concentrated biotech focus with stronger recent returns.

These two healthcare ETFs offer investors exposure to some of medicine's biggest names, but their different approaches to investing could lead to very different results.

AI-driven "biointelligence" is reshaping healthcare investing, with Guardant Health, Illumina, Eli Lilly and Moderna emerging as key stocks as data-driven testing, sequencing and therapies compound.

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifi...

PJP's one-year return beats RSPH's, but RSPH offers broader diversification across 61 healthcare holdings at a lower expense ratio.

VanEck's lower 0.35% expense ratio appeals to cost-conscious investors, while First Trust's $2.9 billion in assets and equal-weighted approach offer broader diversification across 30 biotech holdings.

Check out the companies making headlines yesterday: Harley-Davidson (NYSE:HOG): American motorcycle manufacturing company Harley-Davidson (NYSE:HOG) rose by ...

What Happened? Shares of genomics company Pacific Biosciences of California (NASDAQ:PACB) jumped 9.9% in the afternoon session after EpiSign Inc. and Geneyx ...

What Happened? Shares of genomics company Illumina (NASDAQ:ILMN) jumped 7.7% in the afternoon session after Wall Street analysts lifted their price targets d...

The cancer blood test maker could have a bright future.

What Happened? Shares of genomics company Pacific Biosciences of California (NASDAQ:PACB) jumped 29.7% in the afternoon session after EpiSign announced the l...

Illumina's AI strategy is reshaping the investment case. See how sequencing, biological data, and drug-discovery partnerships could change what drives the company next.

What a fantastic six months it’s been for Illumina. Shares of the company have skyrocketed 126%, hitting $273.47. This was partly due to its solid quarterly ...

Waters (NYSE:WAT) President and Chief Executive Officer Udit Batra said the company’s second-quarter performance exceeded expectations, supported by broad-based growth in its legacy analytical-science operations and early progress integrating acquired Becton Dickinson businesses. Speaking at a JPMo

The global personalized medicine market was valued at USD 567.1 billion in 2024. It is projected to reach USD 656.5 billion in 2026 and USD 1,196.2 billion